



Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE

View Detailed Chart

24.370USD

+0.580+2.44%

Close 04/30, 16:00（ET）Quotes delayed by 15 min

138.10BMarket Cap

17.20P/E TTM



Pfizer Inc

24.370

+0.580+2.44%

Company

Intraday

30m

Today

+2.44%

5 Days

+8.84%

1 Month

-3.33%

6 Months

-14.55%

Year to Date

-8.14%

1 Year

-4.88%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 24 analysts

HOLD

Current Rating

28.771

Target Price

20.94%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

162

Total

Median

Average

Company name

Ratings

Analysts

Pfizer Inc

PFE

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(4)

Neutral(2)

Buy(4)

Indicators

Sell(1)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.507

Neutral

RSI(14)

53.908

Neutral

STOCH(KDJ)(9,3,3)

83.439

Overbought

ATR(14)

0.792

Low Volatility

CCI(14)

181.374

Buy

Williams %R

10.296

Overbought

TRIX(12,20)

-0.473

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

22.986

Buy

MA10

22.612

Buy

MA20

22.760

Buy

MA50

24.705

Sell

MA100

25.446

Sell

MA200

27.019

Sell

News

The Strategic Repositioning Driving Pfizer's Growth Story

TradingKey - Pfizer’s non-COVID portfolio grew 12% in 2024, led by a 65% surge in Vyndaqel sales and 26% oncology revenue growth.

TradingKeyTue, Apr 8

Pfizer sells entire Haleon stake for $3.24 billion

March 19 (Reuters) - Drugmaker Pfizer PFE.N has sold its entire stake in Haleon HLN.L for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.

ReutersWed, Mar 19

Company

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

Company codePFE

CompanyPfizer Inc

CEODr. Albert Bourla, Ph.D.

Websitehttps://www.pfizer.com/